What's wrong with this picture?
Apple is a top-down, buttoned-down, lockstep enterprise managed, after Steve Jobs' death, by his apparatchiks and other relative automatons. Iovine, a producer and impresario from the music industry's bad days, is a promoter and publicity seeker who has often veered toward outr茅 practices and personalities.
So, Apple, teaming up with Iovine, seems either to have a Machiavellian plan of extraordinary vision and incalculable nuance and subtlety, or is taking a wild roll of the dice.
Or both. That is, the Apple of sui generis design and savant marketing, offering among the most singular visions of consumer desire, is over. And now it begins a force-of-will effort to build a more broad-based, if less exceptional, consumer products and entertainment content company. Kind of a Sony (in its better days), with lots of products, some good, some not so good.
Top Tech Companies To Buy Right Now: Sector Spdr Trust Sbi (XLI)
Industrial Select Sector SPDR Fund (the Fund) seeks to provide investment results that correspond to the price and yield performance of the Industrial Select Sector of the S&P 500 Index (the Index). The Index includes companies from industries, such as aerospace and defense, building products, construction and engineering, electrical equipment, conglomerates, machinery, commercial services and supplies.
The Fund utilizes a passive or indexing investment approach to invest in a portfolio of stocks that seek to replicate the Index. The Fund�� investment advisor is SSgA Funds Management, Inc.
Advisors' Opinion:- [By Selena Maranjian]
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some industrial stocks to your portfolio, the Industrial Select Sector SPDR ETF (NYSEMKT: XLI ) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.
The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The SPDR ETF's expense ratio -- its annual fee -- is a very low 0.18%, and it recently yielded about 2%.
This ETF has performed well, outstripping the world market over the past three, five, and 10 years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.
5 Best Healthcare Technology Stocks To Buy Right Now: MiMedx Group Inc (MDXG)
MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, manufacturer and marketer of regenerative biomaterial products processed from human amniotic membrane. The Company�� biomaterial platform technologies include the device technologies HydroFix and CollaFix, and tissue technologies, AmnioFix and EpiFix. Its tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through the Company�� donor program, mothers delivering full-term caesarian births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce a manipulated implant for homologous use. MiMedx is the supplier of amniotic tissue, having supplied over 100,000 implants to distributors and other equipment manufacturers (OEMs) for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
The Company has three platform technologies. Its largest addressable market is in chronic wound care consisting of diabetic, venous and pressure ulcers. On January 5, 2011, the Company acquired all of the outstanding equity interests in Surgical Biologics, LLC. Located in Kennesaw, Georgia, Surgical Biologics develops allografts and other products processed from human amniotic membrane that can be used for a range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon repair, spine repair, burn treatment, and many other types of procedures that require the repair of a patient�� integumental (native) tissue. Surgical Biologics has developed a specialized process for the processing of amniotic membrane to produce a manipulated allograft for homologous use.
AmnioFix and EpiFix
MiMedx is the supplier of allografts processed from amniotic tissue, having supplied over 70,000 allografts to date for application in the Ophthalm! ic, Orthopedic, Dental, Spinal and Wound Care segments of healthcare. Its amnion products, AmnioFix and EpiFix, are processed from human tissue. The AmnioFix and EpiFix allografts can be used for a range of procedures, including ocular surface repair, gingival recession repair, wound care, burns, and many other types of procedures for the repair of a patient�� integumental (native) tissue. Its AmnioFix technology also is used as a graft to reduce the amount of scar tissue formation, provide a local anti-inflammatory and help with the soft tissue healing of the area. EpiFix offers a range of wound healing and wound care options. Much of the clinical usage of EpiFix has been for wound care patients suffering from diabetic ulcers, pressure ulcers, vein circulation ulcers, or artery circulation ulcers.
CollaFix
The Company�� CollaFix technology combines a means of creating fibers from soluble collagen and a specialized cross-linking process. MiMedx utilizes two separate cross-linking technologies for various applications. Initial laboratory and animal testing shows that the cross-linked collagen fibers produce a biocompatible, and durable construct that can be transformed into surgical meshes intended to treat a number of orthopedic soft-tissue trauma and disease disorders.
HydroFix
The Company licenses rights to a polyvinyl alcohol (PVA) polymer, which is a water-based biomaterial that can be manufactured with a range of mechanical properties, including those that appear to mimic closely the mechanical and physical properties of natural, healthy human tissue. This hydrogel has been used in other orthopedic and general surgery device applications, and it has demonstrated biocompatibility and durability inside the human body. It has a similar version of the product for the European market called HydroFix Spine Shield. The device is classified as a post-surgical adhesion inhibiting barrier and is used in specific spine surgeries. In December the original! HydroFix! Spine Shield (for Anterior use Class IIb in Europe) was renamed to be HydroFix Anterior Shield.
The Company competes with W.L. Gore & Associates, Inc. and Stryker.
Advisors' Opinion:- [By Sean Williams]
What: Shares of MiMedx Group (NASDAQ: MDXG ) , a manufacturer of patented regenerative biomaterial products (in essence, products designed to treat inflammation and help wounds heal), were eviscerated, falling as much as 70% at one point before recovering half of its losses after it announced the receipt of an untitled letter from the Food and Drug Administration alleging it does not possess the proper licensing to manufacture certain products.
- [By Teresa Rivas]
The Securities and Exchange Commission charged Arrowood and Petit, CEO of MiMex Group (MDXG), in January of last year. The SEC alleges that Arrowood received non-public information about the potential sale of Matria Healthcare (a publicly traded company that merged with Inverness Medical Innovations in 2008) from Petit, who was CEO of the firm at that time.
- [By Bryan Murphy]
It may not be as big as NuVasive, Inc. (NASDAQ:NUVA), and it might not be as sexy as MiMedx Group Inc. (NASDAQ:MDXG). But, Bacterin International Holdings Inc. (NYSEMKT:BONE) offers something to investors that MDXG and NUVA don't - can't - right now... a distinct opportunity for a lot of upside in a short amount of time.
- [By Garrett Cook]
MiMedx Group (NASDAQ: MDXG) shares were also up, gaining 12.10 percent to $7.04 after the company reported Q2 earnings of $0.00 per share on revenue of $25.60 million and raised its FY14 sales outlook.
5 Best Healthcare Technology Stocks To Buy Right Now: Housing Development Finance Corporation Ltd (HDFC)
Housing Development Finance Corporation Limited is financing by way of loans for the purchase or construction of residential houses, commercial real estate and certain other purposes in India. The Company has a network of approximately 330 offices (which includes 83 offices of its wholly owned distribution company HDFC Sales Private Limited) catering to over 2,400 towns & cities spread across the country. It also has offices in Dubai, London and Singapore and service associates in the Middle East region, to provide housing loans and property advisory services to Non-Resident Indians (NRIs) and Persons of Indian Origin (PIOs). Its product range includes loans for purchase and construction of a residential unit, purchase of plot, home improvement loans, home extension loans, non-residential premises loans for professionals and loan against property, while its flexible repayment options include Step Up Repayment Facility (SURF) and Flexible Loan Installment Plan (FLIP). Advisors' Opinion:- [By MONEYMORNING.COM]
Vanguard favors India with investments in Infosys Ltd. (NSE: INFY), Reliance Industries Ltd. (NSE: RELIANCE), and Housing Development Finance Corp. Ltd. (NSE: HDFC) ranking among its top 20.
5 Best Healthcare Technology Stocks To Buy Right Now: Halozyme Therapeutics Inc.(HALO)
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The company primarily offers recombinant human hyaluronidase, an enzyme that degrades hyaluronan, which is a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. Its portfolio of products and product candidates are developed based principally on intellectual property covering the family of human enzymes known as hyaluronidases. The company also provides Ultrafast Insulin program, a Phase II clinical trial product for the treatment of diabetes mellitus; and Enhanze technology, a proprietary drug delivery platform for subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as sma ll molecules and fluids. It offers PEGPH20, a new molecular entity that is in Phase I trial for the systemic treatment of tumors; and HTI-501, a recombinant human proteinase, which is in Phase 1/2 clinical trial used for the treatment of edematous fibrosclerotic panniculopathy (cellulite). The company has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; ViroPharma Incorporated; and Intrexon Corporation to apply Enhanze technology to the partners? biological therapeutic compounds. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Advisors' Opinion:- [By Monica Gerson]
Halozyme Therapeutics (NASDAQ: HALO) shares dropped 2.04% to $8.12 after the company reported a clinical hold of PEGPH20 pancreatic cancer trial amid voluntary halt.
- [By Anna Prior]
J.P. Morgan (JPM) initiated coverage of Halozyme Therapeutics Inc.(HALO) with an overweight rating and a $13 price target, saying in a note to clients that the company’s proprietary pipeline appears to be garnering increased attention. Halozyme shares climbed 5.2% to $9.77 premarket.
No comments:
Post a Comment